Magali, a village nurse administers the Covid-19 vaccine to senior citizen at the Plan health center, on March 3, 2021 in Plan, Spain. The community of Aragon, Spain, is beginning to vaccinate people who cannot travel to vaccination centers with the Pfizer-BioNtech Covid-19 vaccine at their homes in rural mountain villages.
Alvaro Calvo—Getty Images
After playing a critical role in curbing COVID-19 disease with its vaccine, Pfizer and CEO Albert Bourla late last year introduced an oral antiviral therapy to treat those at highest risk of severe illness. The two-drug combination is the first pill-based coronavirus treatment in the U.S., and can reduce the risk of hospitalization or death by up to 89%. Demand for Paxlovid, which has received emergency-use authorization from the U.S. Food and Drug Administration, will likely increase under the White House’s plan to broaden access to such therapies with its Test to Treat initiative.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
